CCI
CELG

Columbus Circle Investors’s Celgene Corp CELG Stock Holding History

Columbus Circle Investors’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,000
Closed -$2.48M – 316
2017
Q3 		$2.48M Buy
+17,000
New +$2.32M 0.04% 215

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Columbus Circle Investors's CELG Position: Q4 2017 in Review

Columbus Circle Investors sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 575,542 shares — an estimated $82.3M sold.

Columbus Circle Investors first reported a position in CELG in Q2 2013 and held it in 16 quarters. The position peaked at $121M in Q4 2016. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

  • Columbus Circle Investors reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 575,542 Celgene Corp shares in Q4 2017, an estimated $82.3M.
  • Columbus Circle Investors first reported a position in Celgene Corp in Q2 2013 and held it in 16 quarters.
  • Columbus Circle Investors's Celgene Corp position peaked at $121M in Q4 2016.
  • 1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.